<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140088">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277263</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/LAMMP-2010-7789</org_study_id>
    <nct_id>NCT01277263</nct_id>
  </id_info>
  <brief_title>Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging</brief_title>
  <official_title>Predicting Pathological Response Within the 1st Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured With Diffuse Optical Spectroscopic Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with Breast Cancer who do not respond to chemotherapy may undergo months of treatment
      with little or no change in tumor size or overall outcome.

      The Researchers have demonstrated a previously undescribed &quot;metabolic flare&quot; response
      observed very early in neoadjuvant treatment in breast cancer patients. The research can
      determine that this flare is predictive of overall therapy response and is due to both an
      inflammatory reaction and cell death induced by cytotoxic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researcher can use Diffuse Optical Spectroscopic Imaging device to measure and predict
      the markers of the response in the first weeks of chemo-therapy.

      The oxyhemoglobin flare response can predictive of overall pathological response to
      chemotherapy in human subjects. These vascular changes can indicate the rapid transient
      increase and then decrease in oxyhemoglobin concentration in the first hours and days after
      therapeutic administration. The magnitude and time course of the flare response in patients
      receiving cytotoxic therapy will differ between pathological responders and non-responders.
      This oxyhemoglobin &quot;flare response&quot; can be observed In tumors where vascular dynamics are
      intact.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>improve treatment prognosis for breast cancer patients</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proposed research plan has the ability to significantly impact breast cancer research and treatment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diffuse Optical Spectroscopy Imaging</intervention_name>
    <description>Monitoring Breast Cancer during chemo therapy</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      C-Protein serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will be selected from an outpatient population of the Cancer Center
        Clinic, Beckman Laser Medical Clinic of University of California, Irvine and UCI Pacific
        Breast Care. Subjects with the requisite diagnosis of breast cancer will be candidates for
        enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, not pregnant, not breastfeeding

          -  greater than 21 years of age but less than 75 years of age

          -  will be receiving neoadjuvant chemotherapy for breast cancer as prescribed by their
             oncologist

        Exclusion Criteria:

          -  Under 21 year of age

          -  Female pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Tromberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beckman Laser Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ata Sharif, MD, MBA</last_name>
    <phone>949-824-9265</phone>
    <email>sharifs@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas O'Sullivan, PhD</last_name>
    <phone>949.824.8838</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Breast Care Medical Clinic</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ata Sharif, MD, MBA</last_name>
      <phone>949-824-9265</phone>
      <email>sharifs@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Alice Police, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montana Compton, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas D O'Sullivan, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anais Leproux, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Durkin, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Ehren, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beckman Laser Institute</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ata Sharif, MD, MBA</last_name>
      <phone>949-824-9265</phone>
      <email>sharifs@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce Tromberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montana Compton, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Durkin, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anais Leproux, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas O'Sullivan, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Ehren, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ylenia Santoro, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center, UCIMC</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ata Sharif, MD, MBA</last_name>
      <phone>949-824-9265</phone>
      <email>sharifs@uci.edu</email>
    </contact>
    <investigator>
      <last_name>John Butler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montana Compton, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Lane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chaitali Nangia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Ward, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 8, 2017</lastchanged_date>
  <firstreceived_date>January 12, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>Bruce Tromberg, PhD., Director, Beckman Laser Institute and Medical Clinic, Professor, Departments of Biomedical Engineering and Surgery</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
